March 31, 2025 12:00 PM EDT

AstraZeneca’s cholesterol pill is set for Phase 3, but lags behind Merck rival

Elizabeth Cairns

Senior biopharma journalist

AstraZeneca has great ambitions for its mid-stage oral cholesterol drug, believing that it could reach peak sales of more than $5 billion. Positive data presented …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca’s cholesterol pill is set for Phase 3, but lags behind Merck rival

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Firings sweep across FDA as former leaders lament the gutting of drug agency

RFK Jr. has long criticized drug ads. He just slashed the FDA office that regulates them

‘It’ll be a challenge’: BIO chief Crowley addresses seismic FDA overhaul

Sanofi continues its bet on R&D by poaching GSK’s head of development

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

As­traZeneca’s cho­les­terol pill is set for Phase 3, but lags be­hind Mer­ck ri­val

Senior biopharma journalist

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

AstraZeneca’s cholesterol pill is set for Phase 3, but lags behind Merck rival